6
Clinical Trials associated with AZD-2516A Single Centre Two Part Randomized Phase I Study to Assess the Pharmacokinetics of an ER Formulation of AZD2516 and to Assess the Safety, Tolerability and Pharmacokinetics of AZD2516 After Multiple Ascending Doses in Healthy Volunteers
AZD2516 is being developed for the oral treatment of chronic neuropathic pain. This study is split in to two parts. Part A will measure the effect of food and a new formulation of the drug in the blood and see how well it is tolerated. Part B will commence after the completion of Part A and will investigate the safety and tolerability of daily dosing with AZD2516.
A double-blind, randomized, placebo-controlled, two-centre, phase IIa pharmacodynamic cross-over study to assess the effect of AZD2516 on the total number of reflux episodes in healthy male volunteers - PoP study AZD2516
Start Date01 Jun 2010 |
Sponsor / Collaborator- |
A Double-blind, Randomized, Placebo-controlled, Two-centre, Phase IIa Pharmacodynamic Cross-over Study to Assess the Effect of AZD2516 on the Total Number of Reflux Episodes in Healthy Male Volunteers
The purpose of this study is to investigate the pharmacodynamic effect of AZD2516 in healthy male subjects.
100 Clinical Results associated with AZD-2516
100 Translational Medicine associated with AZD-2516
100 Patents (Medical) associated with AZD-2516
100 Deals associated with AZD-2516